Bill Gates mRNA Ebola Vaccine Grant Matches Deadly Outbreak in the Democratic Republic of The Congo (DRC). “Rare and Deadly Virus Strain”
By West Africa Weekly on Global Research. Reposted with permission.
A new Ebola outbreak in central Africa has ignited a firestorm of criticism against billionaire philanthropist Bill Gates, as the timing of a major vaccine funding grant aligns almost precisely with the emergence of a rare and deadly virus strain.
The controversy has deepened further with news that the FBI is investigating an American scientist accused of smuggling pathogen samples out of the Democratic Republic of Congo, the same region now fighting the epidemic.
The outbreak involves the Bundibugyo Ebola strain, which was confirmed by the DRC’s Ministry of Health on May 15, 2026, in Ituri Province. Two days later, the World Health Organization declared a Public Health Emergency of International Concern. Hundreds of suspected cases and dozens of deaths have been reported in an area already suffering from armed conflict and mass displacement.
Just four months before the WHO declaration, in January 2026, the Coalition for Epidemic Preparedness Innovations, or CEPI, awarded 26.7 million dollars to Moderna and Oxford University to develop a multivalent mRNA vaccine against Ebola, specifically including the Bundibugyo strain. CEPI was launched at the World Economic Forum in Davos in 2017, and the Bill & Melinda Gates Foundation was one of its founding donors. Bill Gates has personally championed the coalition since its beginning.
Health researchers on social media have called the timing suspicious, with one widely shared post asking how a vaccine grant for a rare strain could be funded months before that strain caused a global health emergency. Others pointed out that Moderna began developing its mRNA Ebola vaccine using artificial intelligence at the same time the grant was awarded.
The situation took a darker turn when an X account belonging to a public health professional alleged that an NIH virologist named Vincent Munster was caught at a U.S. airport smuggling deadly pathogen samples from the Congo.
The post claimed Munster runs Ebola field sites in the country and regularly conducts gain of function experiments, adding that he is now under FBI investigation. Independent news reports have confirmed that the FBI is indeed investigating Munster over allegations that he smuggled dangerous virus samples, including monkeypox virus, from the Democratic Republic of Congo into the United States.
.
.
Supporters of Gates and CEPI argue that the coalition was created specifically to prepare for future epidemics after the catastrophic 2014 to 2015 Ebola outbreak in West Africa.
They note that the 26.7 million dollar grant was part of a broader effort to develop vaccines against multiple filoviruses, including several Ebola strains and Marburg virus, not just the Bundibugyo strain.
The WHO has also confirmed that no licensed vaccine or specific treatment currently exists for the Bundibugyo virus, meaning the vaccine development is a legitimate public health priority.
Yet the controversy does not exist in isolation.
For years, Bill Gates has faced deep skepticism across Africa over his foundation’s health and agricultural programs. A recent 50 million dollar AI driven health partnership with OpenAI drew sharp criticism, with many Africans accusing Gates of using the continent as a testing ground. Agricultural programs promoted by the Gates Foundation have also been described by some African experts as pushing farmers toward patented seeds and chemical intensive farming, a model they have called a new form of colonization.
As the Ebola outbreak continues to spread and the death count rises, the real world consequences of this distrust are already visible. This week, an angry crowd in the DRC set Ebola hospital tents on fire, demonstrating the dangerous gap between international health efforts and local belief. With the FBI investigation ongoing and the vaccine timeline raising unanswered questions, Bill Gates faces his most difficult challenge yet in Africa.
